M&A - CERO THERAPEUTICS HOLDINGS, INC.

Form Type: 8-K

Filing Date: 2025-05-29

Corporate Action: Merger

Type: New

Accession Number: 000121390025048998

Filing Summary: On May 29, 2025, CERO Therapeutics Holdings, Inc. held its Annual Meeting of Stockholders where various proposals were voted on. Notably, stockholders approved an amendment to the equity incentive plan to increase the common stock shares available for issuance by an additional 2,000,000 shares. Furthermore, the stockholders approved a Corporate Amendment allowing a Reverse Stock Split of common stock at a ratio of one-for-two to one-for-twenty-five, with the Board determining the exact ratio, specifically set at one-for-twenty. This split will take effect at 12:01 a.m. ET on June 10, 2025. The meeting provided a quorum with approximately 52.2% of shares represented, addressing multiple proposals including the election of two Class I directors and the appointment of an independent registered public accounting firm for the fiscal year. The outcomes of these votes are critical for future corporate governance and financial structuring of the company.

Form Type: 10-Q

Filing Date: 2025-05-15

Corporate Action: Merger

Type: Update

Accession Number: 000121390025044335

Filing Summary: Cero Therapeutics Holdings, Inc.'s quarterly report for the period ended March 31, 2025, includes significant updates regarding their financial performance post-merger. The report shows total current assets of $5,768,001 and total liabilities of $8,320,800, indicating a stockholders' deficit of $329,386. The statement highlights operational expenses totaling $4,950,531, primarily due to research and development costs of $2,907,827 and general administrative expenses of $2,042,704. The net loss for the quarter is reported at $5,105,931, leading to a comprehensive loss attributable to common shareholders of $5,454,158. The company also notes forward-looking statements related to future financial performance and drug candidate developments as part of their strategic objectives following the business combination that occurred in 2023. Key risks and uncertainties are acknowledged regarding the operational milestones and market responses to the business combination efforts.